Lantern Pharma Inc expected to post a loss of 45 cents a share - Earnings Preview
03/11/2023 11:29
* Lantern Pharma Inc LTRN.OQ LTRN.O is expected to show
no
change in quarterly revenue when it reports results
*
* Refinitiv's mean analyst estimate for Lantern Pharma Inc
is for
a loss of 45 cents per share.
* The one available analyst rating on the shares is
"hold".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Lantern
Pharma
Inc is $20.5, above its last closing price of $2.74.
This summary was machine generated November 3 at 11:29 GMT. All
figures in US dollars unless otherwise stated
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments